Stonepine Capital Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Stonepine Capital Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-217,395	Closed	-$13.2M	–	34
2018 Q4	$13.2M	Sell	217,395 -67,864	-24%	-$4.05M	11.57%	3
2018 Q3	$16.7M	Sell	285,259 -176,056	-38%	-$8.98M	9.76%	3
2018 Q2	$20.7M	Sell	461,315 -128,710	-22%	-$5.54M	12.58%	1
2018 Q1	$26.2M	Buy	590,025 +204,071	+53%	+$8.57M	14.02%	1
2017 Q4	$16.7M	Buy	385,954 +174,584	+83%	+$7.85M	10.02%	2
2017 Q3	$9.83M	Buy	211,370 +151,492	+253%	+$7.25M	5.8%	10
2017 Q2	$2.96M	Buy	+59,878	New	+$3.14M	1.6%	19
2016 Q3	–	Sell	-30,000	Closed	-$1.2M	–	22
2016 Q2	$1.2M	Buy	30,000 +4,363	+17%	+$160K	1.23%	17
2016 Q1	$893K	Buy	+25,637	New	+$941K	1.05%	14

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TAM

THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Stonepine Capital Management's BSTC Position: Q1 2019 in Review

Stonepine Capital Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2019, closing a stake of 217,395 shares — an estimated $13.2M sold.

Stonepine Capital Management first reported a position in BSTC in Q1 2016 and held it in 9 quarters. The position peaked at $26.2M in Q1 2018. 117 funds tracked by Wall St. Rank hold BSTC as of Q1 2019.

Stonepine Capital Management reported no remaining BioSpecifics Technologies Corp. position as of Q1 2019 after selling out during the quarter.
Stonepine Capital Management sold 217,395 BioSpecifics Technologies Corp. shares in Q1 2019, an estimated $13.2M.
Stonepine Capital Management first reported a position in BioSpecifics Technologies Corp. in Q1 2016 and held it in 9 quarters.
Stonepine Capital Management's BioSpecifics Technologies Corp. position peaked at $26.2M in Q1 2018.
117 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2019.

Based on Stonepine Capital Management's 13F filing for Q1 2019, filed 14 May 2019.